. Author manuscript; available in PMC: 2014 Mar 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):267–274. doi: 10.1097/QAI.0b013e31827b4ac8

Table 4.

Accumulation of resistance mutations during the lag between viral and immunologic failure on first-line cART

ID^§	months on 1^st line after viral failure	Resistance following extended 1^st line treatment during viral failure^□	Accumulation of new resistance mutations
PADX1^*	9	T69N, Y181C, M184V	+ ^Ψ
PADX2^*	12	K103N, V108IV, M184V	+
PADX9^*	8	K101E, M184V, G190A	−
PADC1^*	13	D67del, T69G, K70R, K101H, M184V, G190S, T215F, K219E	+
PADD9^*	8	M41L, D67N, K101EK, Y181C,M184V, T215F	+
PADF2^*	6	D67N, K70R, K103N,M184V, K219E	+
PADG5^*	17	D67N, K70R, K103S, M184V, T215F, K219E	+
PADH3^*	40	D67N, T69N, K70R, A98G, M184V, G190A, T215F, K219Q	+ ^Ψ
PADK4^*	6	L74V, Y115F, Y181C, M184V	− ^Ψ
PADM8^*	17	K103N, M184V, T215TF	+
PADA1^#	27	K103N, M184V	+
PADJ6^#	23	K101EQ, M184V, G190S	+
PADP6^#	27	K103KN	+ ^Ψ
PADB2^#	3	K101EK, K103N, M184V	+
PADC9^#	7	K101E, M184V, G190A	+ ^Ψ
PADG6^#	50	L74V, Y115F, M184V	+
PADH8^#	35	M41L, D67N, V179E, M184V, G190A, L210W, T215Y	+
PADL8^#	1	K103KN, G190AG	−
PADL4^#, ^{^}	23	K103N, M184V	+
PADP4^#, ^{^}	26	A98AG, K101EQ, M184V, G190A	+
PADA7^#, ^{^}	19	K103N, V108VI, M184V	+
PADC6^#, ^{^}	34	none	−
PADD1^#, ^{^}	3	none	−

^§

Some ID numbers present in Table 3 are not included here because some children did not have additional follow-up samples on first-line cART

Switched to PI-based cART based on clinical or immunological criteria

Remained on first-line cART during follow-up

^{^}

No resistance detected at the initial point of viral failure

^□

Mutations in bold were not present at the initial point of viral failure

^Ψ

Had a mutation at the initial point of failure that was no longer detectable after extended 1^st-line cART (compare to Table 3)